AUTHOR INDEX

Volume 71 • 1996

Abe, A. *See* Ozaki, H.
Abe, M. *See* Nagura, J.
Adachi, K. *See* Majima, M.
Akuzawa, S. *See* Nishida, A.
Aniya, Y., Uehara, N., Ishii, C., Suenaga, T., Wada, N., Matsuzaki, T. and Sakanashi, M.
NO formation from nitrates 101
Araki, H. *See* Yamashita, K.

Baba, A. *See* Kitanaka, J.
Ban, T. *See* Sada, H.
Bolton, T.B. *See* Ito, S.

Chachin, M., Shimohama, S., Kunugi, Y.U. and Taniguchi, T.
PKC mRNA levels in Alzheimer's disease 175
Chairungsrilerd, N. *See* Furukawa, Ken-ichi
Chess-Williams, R. *See* Furukawa, Katsuo
Chiba, S. *See* Lakhe, M.
Chikahisa, L. *See* Okazaki, E.
Chikahisa, L., Oyama, Y., Okazaki, E. and Noda, K.
Cell viability and cellular glutathione 299
Chikai, T. *See* Uchida, K.
Corbett, R. *See* Seeman, P.

Dökmeci, D. *See* Karadağ, Ç.H.
Dökmeci, İ. *See* Karadağ, Ç.H.
Duc, N.M. *See* Huong, N.T.T.

Ebara, T., Miura, K., Matsuura, T., Imanishi, M., Yamano, Y., Kim, S. and Iwao, H.
PAF and PG in rat endotoxic shock 247
Egashira, T. *See* Goto, S.

Fujii, T. *See* Morimoto, H.
Fujikura, T. *See* Motoie, H.
Fujimura, A. *See* Sasaki, M.
Fukuchi, I. *See* Kinoshita, K.
Fukuda, T. *See* Iwata, S.
Furukawa, Katsuo, Chess-Williams, R. and Uchiyama, T.
α_{1B}-Adrenoceptor subtypes in rabbit CCP 325
Furukawa, Ken-ichi, Shibusawa, K., Chairungsrilerd, N., Ohta, T., Nozoe, S. and Ohizumi, Y.
A novel inhibitor of Ca^{2+}-pumping ATPase 337
Furukawa, Y. *See* Lakhe, M.

Gomita, Y. *See* Sato, Tomoaki
Goto, S., Egashira, T., Wada, Y., Takayama, F. and Yamanaka, Y.
Fluvoxamine and 5-HT system in monkey 291

Hachisu, M. *See* Nagura, J.
Hamano, S. *See* Ohnota, H.
Hamaoka, S. *See* Sato, Tomoaki
Haruna, K. *See* Ohmori, H.
Hikida, M. *See* Ohmori, H.
Hirose, M. *See* Lakhe, M.
Honda, K. *See* Koizumi, T.
Hori, M. *See* Ozaki, H.
Hui, C. *See* Nagura, J.
Huong, N.T.T., Matsumoto, K., Yamasaki, K., Duc, N.M., Nham, N.T. and Watanabe, H.
Antinarcotic activity of majonoside-R2 345

Ikemura, T., Sasaki, Y., Ishii, H. and Ohmori, K.
KW-4679 inhibits tachykinin release 179
Imaizumi, Y. *See* Ishii, Y.
—— *See* Nagano, N.
Imanishi, M. *See* Ebara, T.
Inatomi, N., Sato, F., Marui, S., Itoh, Z. and Ōmura, S.
Mechanisms of EM574 and motilin action 29
Inoue, H., Nagata, N., Shibata, S. and Koshihara, Y.
Capsaicin and glycyrrhetinic acid derivatives 281
Ishii, C. *See* Aniya, Y.
Ishii, H. *See* Ikemura, T.
Ishii, Y., Muraki, K., Kurihara, A., Imaizumi, Y. and Watanabe, M.
Sematilide on I_K in guinea pig atrium 361
Ito, S. and Bolton, T.B.
IP_3-induced Ca^{2+} release and K^+ current 1
Itoh, Z. *See* Inatomi, N.
—— *See* Iwanaga, Y.
Iwanaga, Y., Miyashita, N., Saito, T., Morikawa, K. and Itoh, Z.
Gastroprokinetic effect of itopride 129
Iwao, H. *See* Ebara, T.
—— *See* Matsuura, T.
Iwata, S., Shimizu, T., Nomoto, M. and Fukuda, T.
Upregulation of D_1-receptor 255

Kanemaru, K. *See* Okazaki, E.
Kaneto, H. *See* Nakao, K.
—— *See* Tokuyama, S.
Kanoh, H. *See* Motoie, H.
Karadağ, Ç.H., Ulugöl, A., Dökmeci, D. and Dökmeci, İ.
Role of H_1-receptors and morphine in MES 109
Karaki, H. *See* Ozaki, H.
—— *See* Trongvanichnam, K.
Kataoka, Y. *See* Yamashita, K.
Katori, M. *See* Majima, M.
Katsuki, H. *See* Nakagami, Y.
Katsumata, O. *See* Majima, M.
Kawabata, M. *See* Nishibori, M.
Kawamuki, K. *See* Motoie, H.
Kawashima, K. *See* Kinoshita, K.
Kawashima, Y. *See* Kinoshita, K.
Kim, S. *See* Ebara, T.
—— *See* Matsuura, T.
Kimura, I., Okabe, M., Ogasawara, M. and Kimura, M.
Competence effect of bFGF on aortic EC 21
Kimura, M. *See* Kimura, I.
Kinoshita, K., Kawashima, K., Kawashima, Y., Fukuchi, I., Yamamura, M. and Matsuoka, Y.
ACh release and turnover by TA-0910 139
Kinoshita, M. *See* Ozaki, H.
Kinukawa, M. *See* Ohnota, H.
Kishimoto, T. *See* Ohmori, H.
Kitamura, T. *See* Ohnota, H.
Kitanaka, J., Takuma, K., Kondo, K. and Baba, A.
Prostanoid-induced glial Ca^{2+} signaling 85
Kizuki, K. *See* Majima, M.
Koizumi, T., Saita, Y., Miyake, A., Nishida, A., Yazawa, H. and Honda, K.

YM022 as human CCK_B antagonist 307
Kondo, J. *See* Takano, M.
Kondo, K. *See* Kitanaka, J.
Konno, F. *See* Nagura, J.
Koshihara, Y. *See* Inoue, H.
Kunugi, Y.U. *See* Chachin, M.
Kurihara, A. *See* Ishii, Y.

Lakhe, M., Furukawa, Y., Yonezawa, T., Nagashima, Y., Hirose, M. and Chiba, S.
Cardiac effects of U-92032 333

Majima, M., Adachi, K., Ohno, T., Ogino, M., Saito, M., Kizuki, K., Katsumata, O., Yamashina, S. and Katori, M.
Kallikrein and oxytocin in SHR 11
Marui, S. *See* Inatomi, N.
Matsuda, A. *See* Morimoto, H.
Matsuda, T. *See* Tsushima, H.
Matsuki, N. *See* Toyoda, M.
Matsumoto, K. *See* Huong, N.T.T.
Matsunaga, K. *See* Sato, Tomoaki
Matsuoka, Y. *See* Kinoshita, K.
Matsuura, T. *See* Ebara, T.
Matsuura, T., Yukimura, T., Kim, S., Miura, K. and Iwao, H.
Effects of ET antagonists on BP and RBF 213
Matsuzaki, T. *See* Aniya, Y.
Meade, C.J., Muacevic, G., Ward, P. and Soyka, R.
Pulmonary pharmacology of DT-TX 30 SE 119
Mitsui-Saito, M. *See* Ozaki, H.
—— *See* Trongvanichnam, K.
Miura, K. *See* Ebara, T.
—— *See* Matsuura, T.
Miyake, A. *See* Koizumi, T.
Miyashita, N. *See* Iwanaga, Y.
Miyata, H. *See* Ohnota, H.
Miyata, K. *See* Nishida, A.
Mori, M. *See* Tsushima, H.
Mori, S. *See* Nishibori, M.
Morikawa, K. *See* Iwanaga, Y.
Morimoto, H., Matsuda, A., Ohori, M. and Fujii, T.
N-type Ca^{2+} channels in sensory nerves 161
Motoie, H., Kanoh, H., Ogata, S., Kawamuki, K., Shikama, H. and Fujikura, T.
Prevention of bone loss by YM175 in dogs 239
Muacevic, G. *See* Meade, C.J.
Muraki, K. *See* Ishii, Y.

Nagano, N., Imaizumi, Y. and Watanabe, M.
Quinacrine on smooth muscle Ca^{2+} channel 51
Nagashima, Y. *See* Lakhe, M.
Nagata, N. *See* Inoue, H.
Nagura, J., Hui, C., Yamamoto, M., Yasuda, S., Abe, M., Hachisu, M. and Konno, F.
Effects of ME3221 in aged-SHRSP 39
Nakagami, Y., Saito, H. and Katsuki, H.
Cytotoxicity of 3-hydroxykynurenine 183
Nakamura, F. *See* Tokuyama, S.
Nakao, H. *See* Uchida, K.
Nakao, K. *See* Tokuyama, S.
Nakao, K., Takahashi, M. and Kaneto, H.
Central K_{ATP} channel and SIA 269
N.-Nakashima, M. *See* Yamashita, K.
Nakaya, N. *See* Nishibori, M.
Nam, D. *See* Seeman, P.
Nham, N.T. *See* Huong, N.T.T.
Nishibori, M., Nakaya, N., Mori, S., Kawabata, M., Tahara, A. and Saeki, K.
Affinity purification of MIF 259
Nishida, A., Uchida-Kobayashi, A., Takemoto, Y., Akuzawa, S. and Miyata, K.
Gastrin and acid secretion in rats 223
Nishida, A. *See* Koizumi, T.
Niwa, M. *See* Yamashita, K.
Noda, K. *See* Chikahisa, L.
Nomoto, M. *See* Iwata, S.
Nomura, Y. *See* Uchida, K.
Nozoe, S. *See* Furukawa, Ken-ichi

Ogasawara, M. *See* Kimura, I.
Ogata, S. *See* Motoie, H.
Ogino, M. *See* Majima, M.
Ohizumi, Y. *See* Furukawa, Ken-ichi
Ohmori, H., Haruna, K., Okumura, A., Kishimoto, T. and Hikida, M.
Subconjunctival immunization of mice 265
Ohmori, K. *See* Ikemura, T.
Ohno, T. *See* Majima, M.
Ohnota, H., Kitamura, T., Kinukawa, M., Hamano, S., Shibata, N., Miyata, H. and Ujiie, A.
Efficacy of KAD-1229 in NIDDM rats 315
Ohori, M. *See* Morimoto, H.
Ohta, T. *See* Furukawa, Ken-ichi
Oishi, R. *See* Sato, Tomoaki
Oka, T. and Yoshimura, N.
Immunosuppressive therapy in organ transplantation 89
Okabe, M. *See* Kimura, I.
Okamoto, H. *See* Takano, M.
Okazaki, E. *See* Chikahisa, L.
Okazaki, E., Chikahisa, L., Kanemaru, K. and Oyama, Y.
Effect of H_2O_2 on intracellular Ca^{2+} 273
Okumura, A. *See* Ohmori, H.
Omura, S. *See* Inatomi, N.
Oyama, Y. *See* Chikahisa, L.
—— *See* Okazaki, E.
Ozaki, H. *See* Trongvanichnam, K.
Ozaki, H., Abe, A., Uehigashi, Y., Kinoshita, M., Hori, M., Mitsui-Saito, M. and Karaki, H.
Iloprost on vascular smooth muscle 231

Sada, H., Ban, T. and Sperelakis, N.
Taurine and Na^+ channel kinetics 147
Saeki, K. *See* Nishibori, M.
Saita, Y. *See* Koizumi, T.
Saito, H. *See* Nakagami, Y.
—— *See* Toyoda, M.
Saito, M. *See* Majima, M.
Saito, T. *See* Iwanaga, Y.
Sakanashi, M. *See* Aniya, Y.
Sasaki, M. and Fujimura, A.
Lomefloxacin and drug interaction 263
Sasaki, Y. *See* Ikemura, T.
Sato, F. *See* Inatomi, N.
Sato, Tomoaki, Suemaru, K., Matsunaga, K., Hamaoka, S., Gomita, Y. and Oishi, R.
L-Dopa potentiation by H_1 antagonists 81
Satoh, Takashi *See* Uchida, K.
Seeman, P., Corbett, R., Nam, D. and Van Tol, H.H.M.
Dopamine and serotonin receptors 187
Shibata, N. *See* Ohnota, H.
Shibata, S. *See* Inoue, H.
Shibusawa, K. *See* Furukawa, Ken-ichi
Shikama, H. *See* Motoie, H.

Shimizu, T. *See* Iwata, S.
Shimohama, S. *See* Chachin, M.
Soyka, R. *See* Meade, C.J.
Sperelakis, N. *See* Sada, H.
Suemaru, K. *See* Sato, Tomoaki
Suenaga, T. *See* Aniya, Y.

Tahara, A. *See* Nishibori, M.
Takahashi, M. *See* Nakao, K.
—— *See* Tokuyama, S.
Takano, M., Kondo, J., Yayama, K. and Okamoto, H.
Kininogen expression in human fibroblasts 341
Takase, H. *See* Uchida, K.
Takayama, F. *See* Goto, S.
Takemoto, Y. *See* Nishida, A.
Takeuchi, N. *See* Uchida, K.
Takuma, K. *See* Kitanaka, J.
Tanabe, H. *See* Yamashita, K.
Taniguchi, T. *See* Chachin, M.
Taniyama, K. *See* Yamashita, K.
Tokuyama, S., Nakamura, F., Nakao, K., Takahashi, M. and Kaneto, H.
Conditioned place preference of dihydroetorphine 357
Toyoda, M., Saito, H. and Matsuki, N.
No effect of carbon monoxide on learning 205
Trongvanichnam, K., Mitsui-Saito, M., Ozaki, H. and Karaki, H.
ISDN on vascular smooth muscle contraction 167
Tsushima, H., Mori, M. and Matsuda, T.
Neural connections between the bilateral SON 73
Neuropeptides in the PVN and SON 61

Uchida, K., Satoh, Takashi, Chikai, T., Takase, H., Nomura, Y., Nakao, H. and Takeuchi, N.
Cholesterol on bile acid in germ-free rat 113
Uchida-Kobayashi, A. *See* Nishida, A.
Uchiyama, T. *See* Furukawa, Katsuo
Uehara, N. *See* Aniya, Y.
Uehigashi, Y. *See* Ozaki, H.
Ujiie, A. *See* Ohnota, H.
Ulugöl, A. *See* Karadağ, Ç.H.

Van Tol, H.H.M. *See* Seeman, P.

Wada, N. *See* Aniya, Y.
Wada, Y. *See* Goto, S.
Ward, P. *See* Meade, C.J.
Watanabe, H. *See* Huong, N.T.T.
Watanabe, M. *See* Ishii, Y.
—— *See* Nagano, N.

Yamamoto, M. *See* Nagura, J.
Yamamura, M. *See* Kinoshita, K.
Yamanaka, Y. *See* Goto, S.
Yamano, Y. *See* Ebara, T.
Yamasaki, K. *See* Huong, N.T.T.
Yamashina, S. *See* Majima, M.
Yamashita, K., Kataoka, Y., N.-Nakashima, M., S.-Yamashita, Y., Tanabe, H., Araki, H., Niwa, M. and Taniyama, K.
TTC-909 and ischemic hippocampal injury 351
S.-Yamashita, Y. *See* Yamashita, K.
Yasuda, S. *See* Nagura, J.
Yayama, K. *See* Takano, M.
Yazawa, H. *See* Koizumi, T.
Yonezawa, T. *See* Lakhe, M.
Yoshimura, N. *See* Oka, T.
Yukimura, T. *See* Matsuura, T.

SUBJECT INDEX

Volume 71 • 1996

Acetylcholine release 139
Acetylcholine turnover 139
Acid secretion 223
Adrenergic neuron 73
α_{1B}-Adrenoceptor subtype 325
Aging 113
Airway 161
Alzheimer's disease 175
Analgesia 269
Angiotensin AT_1-receptor antagonist 39
Anticonvulsive effect 109
Anti-dinitrophenyl IgE 265
Antidiuresis 61, 73
Anti-emetic action 129
Antinociception 345
Antipsychotic drug 187
Aorta (guinea pig) 231
Aorta (rat) 167
Aortic endothelial cell (rat) 21
Astrocyte 85
ATP-sensitive K^+ channel 269
ATPase 337
Atrium (guinea pig) 361

Basic fibroblast growth factor 21
Bile acid metabolism 113
Bisphosphonate 239
Bone mineral density 239
BQ-788 (*N-cis*-2,6-dimethylpiperidinocarbonyl-L-γ-methylleucyl-D-1-methoxycarbonyltryptophanyl-D-norleucine) 213
Brain (bovine) 259
Brain (monkey) 291

Ca^{2+} (intracellular) 273
Ca^{2+} channel 51
Ca^{2+} channel (L-type) 333
Ca^{2+} channel (N-type) 161
Ca^{2+} channel (T-type) 333
Ca^{2+} mobilization 85, 307
Ca^{2+}-pumping ATPase 337
Ca^{2+}-transient 1
Caged inositol 1,4,5-trisphosphate 1
Calcium restriction 239
cAMP 231
Capsaicin 281
Carbon monoxide 205
Cardiac ventricle 51
Catalepsy 187
Chenodeoxycholic acid 113
5-Chloromethylfluorescein 299
Cholecystokinin-8 307
$Cholecystokinin_B$/gastrin receptor 307
Cholesterol 113
Cholic acid/chenodeoxycholic acid ratio 113
Cholinergic neuron 29, 223
Chronic treatment 167
Cisapride 29
Clozapine 187
Conditional place preference 357
Conscious dog 129
Corpus cavernosum penis (rabbit) 325
Cyclooxygenase 247
Cytotoxicity 299

Delayed rectifier K^+ current 361
Diabetes mellitus 315
Diabetic complication 315
Dietary calcium restriction 239
Dietary cholesterol 113
Dihydroetorphine 357
Diuresis 11
L-Dopa 81
Dopamine D_4-receptor 187
Dopamine uptake 81
Drug interaction 263

Ear edema 281
Edema 281
Electroconvulsive shock 109
EM574 (de(*N*-methyl)-*N*-isopropyl-8,9-anhydroerythromycin A 6,9-hemiacetal) 29
Endothelial cell 21
Endothelin-1 213
Endotoxin 247
Enteric nervous system 29
Ethidium 299

Fibroblast 341
Fibroblast growth factor 21
Flow cytometer 273
Flow cytometry 21
Fluvoxamine 291
FR139317 ((*R*)2-[(*R*)-2[(*S*)-2[[1-(hexahydro-1*H*-azepinyl)]carbonyl]amino-4-methylpentanoyl]amino-3-[3-(1-methyl-1*H*-indoyl)]propionyl]amino-3-(2-pyridyl)propionic acid) 213

$GABA_A$-receptor 345
Gastric motility 129
Gastrin receptor 223
Gastroprokinetic 129
Germ-free rat 113
Glibenclamide 269
Glutathione 299
Glutathione *S*-transferase 101
Glycosylation inhibiting factor 259
Glycyrrhetinic acid derivative 281

Hemodynamics 247
Histamine 109
Histamine H_1-receptor 109
Histamine H_2-receptor 223
Histamine H_1-receptor antagonist 81
Huntington's disease 183
Hydrogen peroxide 273
6-Hydroxydopamine 255
3-Hydroxykynurenine 183
5-Hydroxytryptamine uptake 291
Hypoglycemic agent 315
Hypothalamus 73

Iloprost 231
Immunosuppressive agent 89
Indo-1 1
Inhibitor 119
Inositol 1,4,5-trisphosphate 1
Intracellular Ca^{2+} 273
Ischemia-related delayed neuronal death 351
Isosorbide dinitrate 167
Itopride 129

K^+ channel 269
K^+ current 1, 361
KAD-1229 (calcium (2*S*)-2-benzyl-3-(*cis*-hexahydro-2-isoindolinylcarbonyl)propionate dihydrate) 315
Ki-67 antigen 21
Kininogen 341
KW-4679 ((*Z*)-11-[(3-dimethylamino)propylidene]-6,11-dihydrodibenz[*b*,*e*]oxepin-2-acetic acid monohydrochloride) 179

Learning 205
Lomefloxacin 263
Lung 119
Lymphokine 89

Macrophage migration inhibition factor/glycosylation inhibiting factor 259
Majonoside-R2 345
α-Mangostin 337
ME3221 (3-methoxy-2,6-dimethyl-4-[[2′-(1*H*-tetrazol-5-yl)-1,1′-biphenyl-4-yl]methoxy]pyridine) 39
5-Methylurapidil 325
Microdialysis 139
Morphine 109, 357
Motilin 29
mRNA 175

Na^+ channel 147
Natriuresis 11
Neuronal death 351
Nitrate 101
Nitric oxide 101, 205
Non-insulin-dependent diabetes mellitus 315
Nonprotein thiol 273, 299
Norepinephrine 73

Organ transplantation 89
Outward K^+ current 1
Ovariectomy 239
Oxidative stress 273

Oxytocin 11

Paraventricular nucleus 61
Parkinsonism 187
Parotic lymph node 265
Paroxetine binding 291
Passive avoidance learning 205
Patch clamp 1
Penis 325
Peptidase inhibitor 61
Phenylephrine 325
Platelet (monkey) 291
Platelet-activating factor 247
Propidium iodide 21
Prostacyclin analogue 351
Prostaglandin E_2 341
Protein kinase C 175

Quinacrine 51
Quinolinic acid 183

Relaxation 167, 231
Renal blood flow 213
Renal kallikrein 11
Renal secretion 263

Sarcoplasmic reticulum 337
[^{3}H]SCH23390 (*R*(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine) 255
Sematilide 361
Sensory nerve 161
Serotonin 2-receptor 187
Serpin 259
Smooth muscle 51
Spatial learning 205
Spontaneously hypertensive rat 11
Stable expression 307
Streptozotocin-induced non-insulin-dependent diabetes mellitus rat 315
Stress-induced analgesia 269
Stroke-prone spontaneously hypertensive rat 39, 351
Subconjunctival immunization 265
Substance P 281
Substance P release 161
Supraoptic nucleus 61, 73
Systemic blood pressure 213

TA-0910 ((−)-*N*-[(*S*)-hexahydro-1-methyl-2,6-dioxo-4-pyrimidinylcarbonyl]-L-histidyl-L-prolinamide tetrahydrate) 139
Tachykinin 179
Taurine 147
Thromboxane 119
Thromboxane A_2 85
Thromboxane receptor antagonist 119
Thromboxane synthetase 119
Thyrotropin-releasing hormone 139
Toxicity 89
Transplantation (organ) 89

U-92032 ((7-((bis-4-fluorophenyl)methyl)-1-piperazinyl)-2-2(2-hydroxyethylamino)-4-(1-methylethyl)-2,4,6-cycloheptatrien-1-one) 333
Upregulation 255

Vagal stimulation 179
Vasopressin 61
Vasorelaxation 101
Voltage-clamp 147

WB4101 ((2-(2,6-dimethoxy-phenoxyethyl)-aminomethyl-1,4-benzodioxane) hydrochloride) 325
Whole-cell patch clamp 1

YM022 ((*R*)-1-[2,3-dihydro-1-(2′-methylphenacyl)-2-oxo-5-phenyl-1*H*-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl) urea) 223, 307
YM175 (disodium dihydrogen (cycloheptyl-amino) methylenebisphosphonate monohydrate) 239

Zn-protoporphyrin IX 205